Inventing new medicines: The FGF21 story
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Since the discovery of insulin in 1921, protein therapeutics have become vital tools in the treatment of diabetes mellitus. This heritage has been extended with the comparatively recent introduction of recombinant and re-engineered insulins, in addition to the advent of GLP1 agonists. FGF21 represents an example of a novel experimental protein therapy which is able to induce favorable metabolic effects in various species ranging from rodents to man. The aim of this review is to communicate the story of the FGF21 drug discovery path from identification in a functional in vitro screen, to the eventual evaluation of its utility in patients. Given that the development of FGF21 advanced hand-in-hand with rapidly evolving scientific research around this target, we have also attempted to describe our view of recent developments regarding the mechanistic understanding of FGF21 biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031
Self-citationThe effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · cited 8×
“(E) Finally, LY2405319, an FGF21 analog, was shown to be efficacious in humans, suggesting that FGF21-based therapies may indeed represent a novel therapeutic option [49].”
BackgroundResultInfluentialSelf-citationIdentification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00067-1 · Cited by 847
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830 · cited 2×
“Finally, the initial histological observation of brown fat enrichment in FGF21 transgenic animals [8] later led to the idea of FGF21 being a “browning” agent [8,32–34], a concept which has recently been put forward to explain FGF21-driven increases in energy expenditure in animals [35].”
BackgroundSelf-citationKim, K. H., Jeong, Y. T., Oh, H., Kim, S. H., Cho, J. M., Kim, Y.-N., Kim, S. S., Kim, D. H., Hur, K. Y., Kim, H. K., et al. (2013) · Nature Medicine · doi:10.1038/nm.3014 · Cited by 774 · cited 1×
“Finally, the initial histological observation of brown fat enrichment in FGF21 transgenic animals [8] later led to the idea of FGF21 being a “browning” agent [8,32–34], a concept which has recently been put forward to explain FGF21-driven increases in energy expenditure in animals [35].”
BackgroundKurosu, H., Choi, M., Ogawa, Y., Dickson, A. S., Goetz, R., Eliseenkova, A. V., Mohammadi, M., Rosenblatt, K. P., Kliewer, S. A., & Kuro-o, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704165200 · Cited by 748
Lin, Z., Tian, H., Lam, K. S. L., Lin, S., Hoo, R. C. L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.005 · Cited by 691 · cited 1×
“Nevetheless, Adn / mice were refractory to the glycemic effects of FGF21 [53,87] while full FGF21 efficacy remained intact with regard to lipid lowering.”
Background
Cited by
Adipokines in health and disease
Fasshauer, M., & Blüher, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.014 · Cited by 1,050
Understanding the Physiology of FGF21
Fisher, F. M., & Maratos-Flier, E. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105339 · Cited by 912
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Montagner, A., Polizzi, A., Fouché, E., Ducheix, S., Lippi, Y., Lasserre, F., Barquissau, V., Régnier, M., Lukowicz, C., Benhamed, F., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310798 · Cited by 736
PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
Wang, Y., Nakajima, T., Gonzalez, F. J., & Tanaka, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062061 · Cited by 540
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424
Blüher, M., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.016 · Cited by 399
FGF21 as Modulator of Metabolism in Health and Disease
Tezze, C., Romanello, V., & Sandri, M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00419 · Cited by 315
The pathogenesis and treatment of polycystic ovary syndrome: What’s new?
Bednarska, S., & Siejka, A. (2017) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/59380 · Cited by 284
Fibroblast Growth Factor 21—Metabolic Role in Mice and Men
Staiger, H., Keuper, M., Berti, L., Hrabě de Angelis, M., & Häring, H.-U. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00016 · Cited by 270
Lan, T., Morgan, D. A., Rahmouni, K., Sonoda, J., Fu, X., Burgess, S. C., Holland, W. L., Kliewer, S. A., & Mangelsdorf, D. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.005 · Cited by 261
“These data and the finding that high molecular weight FGF21 derivatives, which presumably cannot penetrate the brain, retain their metabolic actions, led to the hypothesis that adipose is the principal FGF21 target tissue (Kharitonenkov and Adams, 2014).”
BackgroundFGF21 Signals Protein Status to the Brain and Adaptively Regulates Food Choice and Metabolism
Hill, C. M., Laeger, T., Dehner, M., Albarado, D. C., Clarke, B., Wanders, D., Burke, S. J., Collier, J. J., Qualls-Creekmore, E., Solon-Biet, S. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.022 · Cited by 229
“Pharmacological FGF21 treatment reduces body weight, increases energy expenditure, improves insulin sensitivity, and improves lipid metabolism in rodents, nonhuman primates, and humans (Coskun et al., 2008; Gaich et al., 2013; Kharitonenkov and Adams, 2013; Kharitonenkov and DiMarchi, 2017; Potthoff, 2017; Talukdar et…”
BackgroundLaeger, T., Albarado, D. C., Burke, S. J., Trosclair, L., Hedgepeth, J. W., Berthoud, H.-R., Gettys, T. W., Collier, J. J., Münzberg, H., & Morrison, C. D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.044 · Cited by 206
Finan, B., Clemmensen, C., Zhu, Z., Stemmer, K., Gauthier, K., Müller, L., De Angelis, M., Moreth, K., Neff, F., Perez-Tilve, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.014 · Cited by 191
Li, H., Wu, G., Fang, Q., Zhang, M., Hui, X., Sheng, B., Wu, L., Bao, Y., Li, P., Xu, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02677-9 · Cited by 178
Inter‐organ communication: a gatekeeper for metabolic health
Castillo‐Armengol, J., Fajas, L., & Lopez‐Mejia, I. C. (2019) · The EMBO Reports · doi:10.15252/embr.201947903 · Cited by 178
Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1
Samms, R. J., Smith, D. P., Cheng, C. C., Antonellis, P. P., Perfield, J. W., Kharitonenkov, A., Gimeno, R. E., & Adams, A. C. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.046 · Cited by 154
“Accordingly, there has been an intense focus on gaining a better understanding of its mechanism of action (Kharitonenkov and Adams, 2014).”
BackgroundSelf-citationThe search for exercise factors in humans
Catoire, M., & Kersten, S. (2015) · The FASEB Journal · doi:10.1096/fj.14-263699 · Cited by 137
“It is produced by a number of tissues, including liver, white adipose tissue, and pancreas, and also targets a range of tissues (165, 166).”
BackgroundA Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response
Iroz, A., Montagner, A., Benhamed, F., Levavasseur, F., Polizzi, A., Anthony, E., Régnier, M., Fouché, E., Lukowicz, C., Cauzac, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.065 · Cited by 128
Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates
Lundsgaard, A.-M., Fritzen, A. M., Sjøberg, K. A., Myrmel, L. S., Madsen, L., Wojtaszewski, J. F. P., Richter, E. A., & Kiens, B. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.11.001 · Cited by 126
Hepatokines: unlocking the multi-organ network in metabolic diseases
Iroz, A., Couty, J.-P., & Postic, C. (2015) · Diabetologia · doi:10.1007/s00125-015-3634-4 · Cited by 111
“FGF21 has been noted as a promising pharmacological target because of its ability to reduce blood glucose independently of insulin by increasing the expression of glucose transporter GLUT1 in human primary adipocytes [2].”
BackgroundMetabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis
Markan, K. R., & Potthoff, M. J. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.09.021 · Cited by 103
“Alternatively, a number of studies have reported that extended administration of FGF21 induces a thermogenic gene expression profile in both white and brown adipose tissue [23,50] including induction of uncoupling protein 1 (UCP1), a specialized inner mitochondrial membrane protein which dissipates chemical energy as…”
BackgroundFGF21 and the physiological regulation of macronutrient preference
Hill, C. M., Qualls-Creekmore, E., Berthoud, H.-R., Soto, P., Yu, S., McDougal, D. H., Münzberg, H., & Morrison, C. D. (2020) · Endocrinology · doi:10.1210/endocr/bqaa019 · Cited by 99
Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action
Ost, M., Coleman, V., Voigt, A., van Schothorst, E. M., Keipert, S., van der Stelt, I., Ringel, S., Graja, A., Ambrosi, T., Kipp, A. P., et al. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2015.11.002 · Cited by 75
Implication of hepatokines in metabolic disorders and cardiovascular diseases
Jung, T. W., Yoo, H. J., & Choi, K. M. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.03.002 · Cited by 71
“Therefore, hepatokines have been suggested to be predictive biomarkers of NAFLD, T2DM, and CVD.”
BackgroundInfluentialHomeostatic sensing of dietary protein restriction: a case for FGF21
Hill, C. M., Berthoud, H.-R., Münzberg, H., & Morrison, C. D. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.06.002 · Cited by 68
Sex differences in the hormonal and metabolic response to dietary protein dilution
Larson, K. R., Russo, K. A., Fang, Y., Mohajerani, N., Goodson, M. L., & Ryan, K. K. (2017) · Endocrinology · doi:10.1210/en.2017-00331 · Cited by 66
Association between serum FGF21 level and sarcopenia in older adults
Jung, H.-W., Park, J. H., Kim, D. A., Jang, I.-Y., Park, S. J., Lee, J. Y., Lee, S., Kim, J. H., Yi, H.-S., Lee, E., et al. (2021) · Bone · doi:10.1016/j.bone.2021.115877 · Cited by 55
Role of exercise-induced hepatokines in metabolic disorders
Ennequin, G., Sirvent, P., & Whitham, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00433.2018 · Cited by 54
Stemmer, K., Zani, F., Habegger, K. M., Neff, C., Kotzbeck, P., Bauer, M., Yalamanchilli, S., Azad, A., Lehti, M., Martins, P. J. F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3668-7 · Cited by 44
“Nevertheless, the pharmacological application of FGF21 holds promise as an effective therapeutic means for treating obesity and diabetes [20–25] despite uncertainty remaining regarding its physiological role as endocrine mediator of ketogenic adaptations.”
BackgroundWillis, S. A., Sargeant, J. A., Yates, T., Takamura, T., Takayama, H., Gupta, V., Brittain, E., Crawford, J., Parry, S. A., Thackray, A. E., et al. (2020) · The Journal of Nutrition · doi:10.1093/jn/nxz333 · Cited by 34
Metadata
- Authors
- Kharitonenkov, A., & Adams, A. C.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 3
- Issue
- 3
- Pages
- 221-229
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W1964063591
- Cited by
- 198
- References
- 45
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.